These peptides include proteins involved in cancer metastasis and apoptosis regulation, with the capacity to selectively bind either NKG2A or the counterpart NKG2C activating receptor, thereby expanding the regulatory potential on cytotoxic lymphocytes expressing varying levels of CD94/NKG2x receptors [27]. The gene discussed is KLRC1; the disease is cancer.